To paraphrase the old saying, every silver lining has a cloud. Levodopa remains the gold standard of symptomatic relief because it works, but as Parkinson's Disease (PD) progresses and the therapeutic window of levodopa narrows, many people with Parkinson's (PwP) develop involuntary movements. This phenomenon is termed levodopa-induced dyskinesia (LID), despite the fact that the mechanism of LID is much more complex.
INTRODUCTION
To paraphrase the old saying, every silver lining has a cloud. Levodopa remains the gold standard of symptomatic relief because it works, but as Parkinson's Disease (PD) progresses and the therapeutic window of levodopa narrows, many people with Parkinson's (PwP) develop involuntary movements. This phenomenon is termed levodopa-induced dyskinesia (LID), despite the fact that the mechanism of LID is much more complex.
At this point we would like to comment on the nomenclature from the perspective of PwPs. The term "levodopa-induced dyskinesia" suggests that dyskinesia appears purely as a result of taking levodopa. In reality, it is now widely accepted that the emergence of dyskinesia in the course of the disease refl ects progressive neurodegeneration, not the duration of levodopa therapy. Unfortunately, the mistaken view that levodopa can only be taken for a certain length of time persists, leading to widespread "levodopa-phobia". Perhaps a small step towards dispelling this myth is to simply describe the symptoms as "dyskinesia".
The review below provides a summary of the prevalence and current understanding of the pathogenesis of dyskinesia followed by a Phase 3 study in spotlight of amantadine ER, the only molecule currently approved for management of dyskinesia in PD and then a review of the novel therapeutic options in development.
PATHOGENESIS OF DYSKINESIA
Dyskinesia are involuntary hyperkinetic movements presenting mostly as chorea or choreoathetoid form, but rare ballistic, dystonic or stereotypical variants have been described as well. Various subtypes of dyskinesia and body distribution have been recently summarized in a review by Espay et al. [1] . Briefl y, dyskinesia can be classifi ed as peak dose and diphasic. The body distribution, timing and even treatment strategies for the two subtypes differ [1] .
The risk of developing dyskinesia is approximately 25-40% after 4-6 years of levodopa therapy and increases thereafter. Dyskinesia impacts both the social and functional aspects of one's life. Even though surveys validate a signifi cant negative impact of dyskinesia on social life, patients continue to prefer to be ON with dyskinesia instead of being OFF [2] . Understanding the pathophysiology of dyskinesia aids in developing newer and redirecting established drugs for adequate management.
For a long time, it was believed that levodopa therapy was a major cause of dyskinesia. However, preclinical data have demonstrated that levodopa therapy may sensitize the nigrostriatal system but does not induce dyskinesia in the setting of preserved dopaminergic circuit [3] . Data from numerous clinical studies have established that delaying levodopa initiation does not prolong the latency to dyskinesia onset. Accordingly, dyskinesia is not a result of duration of levodopa therapy but rather a combination of various intrinsic and extrinsic factors.
With the loss of striatal dopaminergic innervation, the aromatic amino acid decarboxylase within serotonin neurons is used to convert exogenous levodopa to dopamine. Consequently, the dysregulated dopamine delivery and maladaptive serotonergic transmission is linked to expression of dyskinesia [9] . Preclinical data on modulating 5-HT receptors to control dyskinesia has been promising and serve as the rationale for targeting the serotoninergic system.
Other major systems within the basal ganglia linked to dyskinesia include cholinergic, opioid, adrenergic and the cannabinoid system [1] . The current clinical trials and available therapies focus on symptomatic management but there is a need to ultimately direct our attention towards preventing the development of dyskinesia in the fi rst place. 
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PHASE 3 IN FOCUS -ADAMAS PHARMA'S GOCOVRI
Background: The Phase 3 in focus for this edition of Clinical Trial Highlights continues the theme of symptomatic relief of dyskinesia in PD. We will review two Phase 3 trials already completed on amantadine ER (Gocovri), previously known as ADS-5102 during development, EASE LID [1] and EASE LID 3 [2] .
Gocovri is a capsule containing 137mg extended-release amantadine, an uncompetitive antagonist at the N-methyl-D-aspartate receptor known to have benefi t to relieve the symptoms of dyskinesia and currently the only available molecule for management of dyskinesia. The rationale of extended release is to provide a therapeutic level of amantadine in the blood for a longer period of time, in this case enabling once a day dosing. Two capsules are administered at bedtime to give a slow increase during sleep, peak levels in the morning and a sustained concentration during the day.
Comments:
The primary outcome measure was the change in the Unifi ed Dyskinesia Rating Scale (UDysRS) which has a range from 0 to 104. This is in common with most of the clinical trials for dyskinesia in PD.
The two trial plans are summarised in Table 1 below. The designs were very similar, with differences only in the additional extended timepoint of 24 weeks and some secondary outcomes, for example, the use of Clinician's Global Impression of Change (CGIC) in EASE LID.
Among the inclusion criteria for EASE LID were a score of at least 2 on question 4.2 of the Unifi ed Parkinson's Disease Rating Scale (UPDRS); at least two episodes of half an hour of troublesome dyskinesia when ON; and at least 3 administrations of levodopa per day. Exclusion criteria included a history of dyskinesia that was exclusively diphasic, OFF state, myoclonic, dystonic, or akathetic without peak-dose dyskinesia. The inclusion and exclusion criteria for EASE LID 3 did not specify these restrictions, although the baseline data would indicate that these criteria would be met comfortably. 
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The results from both trials are summarized in Table 2 There were no signifi cant differences in the UPDRS score (total or parts I, II or III) between Gocovri and placebo at either 12 or 24 weeks, suggesting Gocovri does not make other PD symptoms worse.
In the EASE LID study, adverse events (AEs) were recorded for 88.9% of Gocovri participants, compared to 60.0% in the placebo group. Most were mild to moderate, at 68.3% (Gocovri) and 53.8% (placebo). The most common AEs, at 5% in the active arm, included visual hallucinations, peripheral edema, dizziness, dry mouth, and constipation. Other AEs occurring in less than 5% of participants in the Gocovri group included nausea (4.8%), confusion (3.2%), and orthostatic hypotension (1.6%) [1] .
Visual hallucinations were reported by 15 participants (23.8%) in the Gocovri group and 1 participant in the placebo group. One report in the active group was classed as severe but did not meet the criteria for a serious AE. Thirteen participants (20.6%) in the Gocovri group discontinued the study drug because of AEs as did 4 participants (6.7%) in the placebo group [1] .
In the EASE LID 3 trial, AEs were reported for 84% of Gocovri participants and 50% on placebo. Most reported AEs were classed as mild to moderate (70% with Gocovri and 45% with placebo). The most common AEs with an incidence of 5% in the Gocovri group were dry mouth, nausea, decreased appetite, insomnia, orthostatic hypotension, constipation, falls, and visual hallucinations. One participant reported 2 Gocovri-related serious AEs (constipation and urinary retention) [2] .
A further participant on Gocovri experienced suicidal ideation (assessed by the investigator as related to the study drug), and a second participant attempted suicide (assessed by the investigator as not related to the study drug). Nineteen percent of the Gocovri group and 8% of placebo participants discontinued the study because of AEs [2] .
Although Gocovri has not been compared to immediate release (IR) amantadine in a directly comparative effi cacy study, there is a pharmacokinetic comparison showing Gocovri, administered once a day at bedtime, has a delayed time to maximum plasma concentration (12-16 hours), with a sustained level of amantadine throughout the day [3] . The steady state profi le of Gocovri was signifi cantly different to that of IR amantadine administered twice daily, such that the two formulations are not bioequivalent.
The results clearly show a statistically and clinically signifi cant improvement in ON time without troublesome dyskinesia and a concomitant reduction in time with troublesome dyskinesia. Further analyses of the participant diaries have been published using pooled data from both trials [4] .
Osmotica Pharmaceuticals has recently launched an extended release amantadine preparation (Osmolex ER) in the US. The new drug is approved for the treatment of PD and for drug induced extrapyramidal reactions in adults. Two Phase 3 trials were conducted for dyskinesia, ALLAY-LID-I (NCT02153645) and ALLAY-LID-II (NCT02153632). Despite this, the New Drug Application (NDA) was based on bioequivalence to amantadine and Osmolex ER does not have the LID indication. It is not interchangeable with either amantadine or Gocovri.
Many PwP fi nd dyskinesia one of the most distressing and embarrassing symptoms of PD, restricting social interaction and causing other knock-on effects such as weight loss. Therapies that prevent dyskinesia or replace the troublesome kind will be valuable tools to use in PD. While Gocovri is a valuable addition to the treatment armamentarium, it does have a fairly high incidence of drug induced adverse effects and as such the development of novel therapeutics remains of value. These are reviewed further in this issue. 
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EXPERIMENTAL THERAPIES FOR DYSKINESIA IN THE CLINIC
There are eight therapies in clinical phase, summarised in Table 1 below. Seven of the programs are listed on www.clinicaltrials.gov, these will be described in more detail later in this article. There are around a million people in the US with PD of whom an estimated 150,000 to 200,000 suffer from associated dyskinesia [2] . This is one reason why LID has been classifi ed by the US FDA as an orphan disease.
When compared to clinical trials measuring the infl uence of a therapy on the progression of PD, studies measuring symptom relief require a much shorter assessment time. The duration of intervention for the dyskinesia therapies under review varies from seven days to twelve weeks, although the former (Oregon University) includes a twoweek titration period and an assessment at six weeks post-treatment initiation.
All the projects have the Unifi ed Dyskinesia Rating Scale (UDysRS) as the primary outcome, with only one study having additional primary outcomes. This focus on effi cacy is complemented by secondary outcome measures that include the Unifi ed Parkinson's Disease Rating Scale (UPDRS). Some studies have started to include digital technology as exploratory outcomes hoping to collect more real life data. All of the targets are alternative, non-dopaminergic neurotransmitter systems, aiming to reduce dyskinesia while ideally retaining the positive benefi ts of levodopa. One program is focused on the glutamate pathway, using negative allosteric modulation of metabotropic glutamate receptors.
Clevexel Pharma were developing CVXL-0107 (naftazone), a glutamate release inhibitor. This mode of action is thought to help relieve the symptoms of dyskinesia by reducing cortical input to the striatum; decreasing globus pallidus-mediated movement inhibition; and slowing down neurodegeneration through inhibition of excitotoxicity. Pre-clinical data then a multiple n=1 study [5] suggested that naftazone may have antiparkinsonian and antidyskinetic properties. A Phase 2a study (NCT02641054) was initiated to test the hypothesis but showed no difference between naftazone and placebo [6] . 
Clinicaltrials.gov ID: NCT01336088
Sponsor: Addex Pharma.
Enrolment: 83
Completion: February 2012
Study Design: Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Study to Evaluate the Safety, Tolerability and Effi cacy of ADX48621 (dipraglurant). The trial design contained a dose escalation from 50mg once daily up to 100mg three times a day.
Outcome Measures: The primary outcome measure was the number of participants with abnormal safety and tolerability assessment parameters after 4 weeks.
Secondary outcome measures were the severity of dyskinesia as measured by the modifi ed Abnormal Involuntary Movement Scale (mAIMS) after 4 weeks; change in PD severity as measured by participant diary at weeks 1, 2, 3 and 4, UPDRS part III at weeks 2 and 4, UPDRS total score at week 4; and participant and clinician-rated global impression of change in dyskinesia and PD at 4 weeks.
Comments:
The dipraglurant treatment group of 52 participants had a higher incidence of adverse events (AEs) -88.5% -than the placebo group of 24 (75%). While most participants completed the dose escalation, 2 participants in the active group discontinued due to AEs. No treatment effects were seen in safety monitoring variables.
Dipraglurant had a statistically signifi cant effect against placebo as measured by mAIMS on day 1 (19.9% vs 4.1%). By day 28 a strong placebo response (21.5%) compared to the dipraglurant measure (31.4%) meant that statistical signifi cance was not achieved at the end of the study.
The clinician-rated global impression of change showed a statistically signifi cant improvement with dipraglurant (71.2%) versus placebo (49.9%). According to participant diaries, daily on time with dyskinesia reduced and on time without dyskinesia increased.
Two pivotal Phase 3 studies are scheduled to start by the end of 2019. Both studies plan the same enrolment (200 participants) split equally between dipraglurant and placebo, with the same primary and secondary outcomes. The fi rst study (#301) will start an open label extension (OLE) after 3 months; the second study (#302) starts the OLE after 6 months. The Phase 3 studies are expected to report results in the third quarter of 2021.
As with other experimental therapies for dyskinesia, dipraglurant has been granted orphan drug status by the US FDA, allowing seven years of market exclusivity. Though it also interacts with other receptors in the 5-HT system, it has strong affi nity towards 5-HT1A/B receptors thought to be primarily responsible for its action. Initially introduced in studies for pathological aggression in intellectually disabled patients, it has since been repurposed to study its effect in ADHD, dementia, and PD patients. Though clinical benefi t for aggression is still inconclusive, its safety and tolerability have been demonstrated in human trials in both oral and intravenous forms [1] .
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In preclinical animal models, eltoprazine was shown to signifi cantly reduce dyskinesia in levodopa primed models in a dose dependent fashion. When used in combination with levodopa in drug naïve models, it demonstrated protective effect. At lower dose, it was also shown to potentiate the anti-dyskinetic effect of amantadine. However, the benefi t in dyskinesia came with mild loss of anti-parkinsonian benefi t of levodopa [2] .
Based on positive results from the preclinical data, PsychoGenics along with the Michael J Fox Foundation funded a double blind, placebo-controlled Phase 1/2a study exploring the safety profi le and effi cacy of eltoprazine for dyskinesia in PD participants. A total of 24 participants were recruited across two sites in Sweden. As a dose fi nding study, this trial looked at the ability of eltoprazine to suppress dyskinesia in PD participants after single dosing administered along with levodopa, while maintaining the benefi ts of levodopa. The three tested doses of Eltroprazine, i.e. 2.5mg, 5mg or 7.5mg, were pre-selected on the basis of safety profi le from previous trials in non-PD participants. Compared to randomized placebo dosing, 5mg single dose was shown to have statistically signifi cant reduction in dyskinesia up to 3 hr post dosing. The 2.5mg and 7.5mg doses showed clinical improvement but failed to reach statistical signifi cance. The dosing was safely tolerated without altering levodopa benefi ts [3] . Though the benefi ts were modest, the trial successfully paved the way for the Phase 2 studies. Study Design: This is a double blind, placebo-controlled, crossover, dose range fi nding interventional study designed to assess the safety, tolerability, and effi cacy of eltoprazine on dyskinesia in PD participants. They are exploring 3 treatment doses and will assess their effi cacy as compared to the placebo on the severity of dyskinesia, parkinsonian symptoms and participant function along with safety and tolerability. The study uses standard scales as noted below along with motion sensors and electronic diaries.
The inclusion criteria require individuals between 30 to 85 years of age with a diagnosis of PD of at least 3 years duration and should be on stable dose of levodopa for 4 weeks prior to screening visit. The dyskinesia is required to be 1. moderate to severely disabling 2. present during 25% of the waking day on an average, and 3. present for at least 3 months prior to study entry.
Standard exclusionary criteria are applied. Participants with surgical treatment for PD namely DBS are not blindly excluded but will be, if the procedure was done within the last 6 months of study inclusion or is planned during the study.
There are 4 study arms as noted here, all with dosing for 3 weeks: 1. Eltoprazine HCl 2.5mg BID (5mg/day) 2. Eltoprazine HCl 5mg BID (10mg/day) 3. Eltoprazine 7.5mg BID (15mg/day) 4. Placebo capsules BID Participants will be randomly assigned to each of the 4 arms. They will complete the 3-week treatment cycle before crossing over to the next study arm.
The study is being conducted in USA at the Parkinson's Disease and Movement Disorders Center at Boca Raton, FL.
Outcome:
The primary outcome measure is the change in the total UDysRS score. This will be assessed at the end of each treatment period on days 21, 42, 63 and 84.
Secondary outcome measures will include 1. Effect on PD motor symptoms as assessed by MDS-UPDRS, participant diaries and physiological measurement using the motion sensor system after 84 days. 2. Change in dyskinesia severity using the physiological motion sensor system after 84 days. 3. Participant function using the questionnaires in MDS-UPDRS and UDyRS to quantify dyskinesia and parkinsonian motor symptoms. This will also be assessed after 84 days. 4. Lastly, safety and tolerability as assessed by adverse events, physical and neurological exams, safe laboratory values, vital signs and ECG. This will be assessed after 94 days.
Current status
Though listed as active and not recruiting, it is unknown if they have met the target already. The Clinicaltrials. gov website has not been updated and no results have been posted yet.
Comments:
The molecule carries potential for meaningful benefi t in dyskinesia. The design of the Phase 1/2a study limits any effective assessment of effi cacy. In 2016, the US FDA granted the molecule orphan drug designation status for PD. Since 2017, Eltoprazine's development has been handled by Elto Pharma, Inc., a joint venture between Amanrantus and PsychoGenics. Elto Pharma recently entered into agreement with Coeptis Pharmaceuticals, Inc. regarding further development.
Though the results from the phase 2b study were expected by now, given the delay, we will have to wait to fi nd out whether the molecule is truly effi cacious for dyskinesia without compromising the levodopa benefi ts. 
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BUSPIRONE PROGRAMS
Background: Buspirone is an established anxiolytic that acts primarily on the serotonergic system. Though it also affects the 5-HT2 receptors and is an antagonist for the D2 receptor, its effi cacy is thought to be primarily mediated through the 5-HT1A receptors. Given the evidence of serotonergic involvement in Parkinson'sassociated dyskinesia, a number of studies are testing buspirone in PD. Previous human trials have established a safe profi le of the drug and it has a comparatively lower risk of serotonin syndrome [1] .
Preclinical data suggests that buspirone is effective in reducing dyskinesia and physiologically reduces the fi ring rate of subthalamic neurons but requires an intact nigrostriatal pathway to do so [2] . Buspirone has been studied in open label trials previously exploring its effect on parkinsonism and dyskinesia. Studies that looked specifi cally into buspirone's role for parkinsonism demonstrated no benefi t at lower doses (30mg/kg) but had worsening of parkinsonism with anti-dyskinetic benefi t at higher doses (~100mg/day) [3, 4] . However, when explored specifi cally for dyskinesia in open label studies, benefi t was noted in low to moderate dose (15-60mg/ day) with variable worsening of parkinsonism [5, 6] . The anti-dyskinetic benefi t was noted only in moderate to severe cases [6] .
Recent clinical data from three PD patients with off state dyskinesia post fetal neural graft are of interest. Imaging studies showed increased serotonergic innervation of the striatum and all three had signifi cant suppression of dyskinesia after using buspirone [7, 8] . This supports the serotonergic hypothesis and lays the groundwork for further studies to determine effi cacy in dyskinesia. Study Design: The study is a phase 3 multicenter, randomized, placebo-controlled, double-blind trial looking at the effi cacy of buspirone in reducing dyskinesia in PD participants. They aim to enrol 100 clinically diagnosed PD participants between 35 to 80 years of age. The dyskinesia is required to be moderately disabling and to be present more than 25% of the waking time. The participant should be able to identify dyskinesia, ON and OFF periods. They should be on stable antiparkinsonian medications and be considered optimally treated at the time of inclusion. Standard exclusionary criteria are applied. Participants with DBS can be included if the procedure was done 12 months before inclusion and they are on stable stimulation parameters for at least 4 weeks prior to the fi rst visit.
ASSISTANCE PUBLIQUE -HOPITAUX DE PARIS
The study will randomly assign participants to two study arms. Arm 1 will receive buspirone orally in escalating doses. For the fi rst two weeks, they will be on 10mg daily morning dose followed by 10mg twice a day for the next two weeks to fi nally build up to 10mg three times a day from week 5 to 12. Arm 2 will receive capsules of placebo and administered in escalating doses to match the arm 1. Assessments will be done every 2 weeks and at the end of the study.
Outcome: The primary outcome evaluates change in the UdysRS between the placebo and treatment arm from baseline to week 12.
Secondary outcomes include: 1. Comparison of effi cacy between the two arms as measured by MDS-UPDRS parts 3 and 4 at different time points within the period of 13 weeks treatment duration. 2. Comparison of quality of life between the two arms as measured by MDS-UPDRS parts 1 and 2 at different time points within the 13 weeks treatment duration. 3. Comparison between the two arms as measured by side effects profi le at different time points within the 13 weeks treatment duration. 4. The maximum dose tolerated by the participants at different time points within the 13 weeks treatment duration.
IRL-790 -INTEGRATIVE RESEARCH LABORATORIES
Background: IRL-790 is a dopamine D3 receptor antagonist with psychomotor stabilising properties. A previous Phase 1b study with IRL-790 in 15 participants (NCT03531060) using the UDysRS to assess symptoms showed a median reduction of 11.5 points vs placebo and a mean reduction of 8.2 points vs placebo over four weeks. There was no effect on standard anti-Parkinsonian medication. Inclusion criteria require PwP between the ages of 18 and 79 on a stable regimen of anti-parkinsonian medication. They must display waking day dyskinesia of 25% determined as a score of 2 on question 4.1 of the UPDRS part IV. One intriguing inclusion criterion is that participants must be willing and able to avoid direct exposure to sunlight from day 1 to day 28.
Outcome Measure: Primary outcome: the UDysRS score at 4 weeks. Secondary outcomes are also focused on effi cacy, all measured at 4 weeks: 1. UDysRS parts III and IV. 2. Participant diaries assessing change in daily off time, measured every half hour during 24 hours at visit 1. 3. UPDRS part III. 4. UPDRS part IV questions 4.1 and 4.2 related to dyskinesia.
Comments: This study is a Phase 2a study to further assess effi cacy of IRL-790 in the reduction of dyskinesia. The trial is still in the early stages but it will be interesting to see if D3 antagonism can deliver anti dyskinetic benefi ts without compromising motor control.
PRIDOPIDINE
Background: Pridopidine, developed by Arvid Carlsson Research Laboratories, is a potential neuroprotective and neurorestorative molecule shown to exert its effect via the sigma-1 receptors. It has mostly been explored for Huntington's Disease (HD) and was given orphan drug status by FDA for HD. Teva pharmaceuticals took over the development of the drug from NeuroSearch in 2012, but given the lack of positive data from the HD trials Teva is letting go of the molecule and Prilenia Therapeutics Development Ltd. has taken over its development.
In experimental PD animal studies, pridopidine has been shown to protect the nigral dopaminergic cell bodies and upregulate growth factors leading to axonal sprouting and restoration of striatal dopaminergic fi bre density.
The nigral neuroprotective effect has been associated with reduced microglial activation [1] . Preclinical data in PD models demonstrate dose dependent reduction in dyskinesia up to 71% without jeopardizing the antiparkinsonian benefi ts of levodopa. There was also a notable reduction in ON time with disabling dyskinesia [2, 3] .
Most of the data for pridopidine comes from HD trials. Though the trials fail to demonstrate consistent signifi cant benefi t in motor impairment in HD participants, all the studies established a safe and tolerable profi le for the drug [4] [5] [6] . Since the safety profi le is established, the molecule is being explored for dyskinesia in a Phase 2 trial as detailed below. Objective: A multicentre, randomized, double-blind, placebo-controlled, Phase 2 study evaluating the effi cacy, safety, and pharmacokinetics of investigational drug pridopidine as compared to placebo for the treatment of LID in PD participants.
Title
Status: Recruiting
Clinicaltrials.gov Identifi er: NCT03922711
Sponsor: Prilenia Therapeutics
Estimated Enrolment: 135 participants
Estimated Primary Completion Date: April 2020
Study Design: This is a multicentre, double-blind, randomized, three-arm, parallel-group Phase 2 study evaluating the effi cacy and safety of two doses of pridopidine vs placebo for dyskinesia in PD participants. The study will include participants with a clinical diagnosis of PD between the ages of 30 and 85 years. Mild to moderate dyskinesia is a prerequisite. Participants are required to be on a stable medication regimen (PD and non-PD) for at least 28 days prior to the study start date and be able to maintain that through the study duration. Standard exclusionary criteria apply. Participants with surgical intervention such as DBS are excluded.
The participants will be randomized to one of 3 parallel arms: Arm 1-dose 1 in the form of oral capsules for 12 weeks following a 2 week titration period. Arm 2-dose 2 in the form of oral capsules for 12 weeks following a 2-week titration period. Arm 3-placebo in the form of oral capsules for 14 weeks.
The study is currently recruiting participants at two sites in the USA.
Outcome:
The primary outcome measure explores the change in dyskinesia from baseline to week 14. The score is calculated as a sum of parts 1, 3, and 4 of the UdysRS. No secondary outcomes have been posted.
Comments:
The pharmacology of the molecule and data from animal studies are promising. Given an established safety profi le, it is one step ahead in the development for dyskinesia. Physiologically its effect is similar to GDNF growth factors in terms of neuronal dopamine protection and sprouting in the nigrostriatal axons. Though it failed to show effi cacy for the HD population, its effect on dyskinesia is yet to be determined.
